一个以访问为重点的以患者为中心的价值评估框架,用于免疫介导炎症疾病中的药物表单决策
Min Yang1,2, Manish Mittal3,4, A Mark Fendrick5
1Analysis Group, Boston, MA, USA.
Advances in therapy
|December 20, 2024
概括
一个以患者为中心的新框架改善了美国针对免疫媒介炎症疾病 (IMIDs) 的药物获取. 这种方法优先考虑快速,可预测和持续的治疗方法,提高患者的治疗结果和护理连续性.
科学领域:
- 卫生经济学和结果研究研究.
- 药物经济学 药物经济学
- 卫生政策 卫生政策
背景情况:
- 美国医疗保健系统是分散的,导致药物获取和配方政策的变化.
- 管理免疫媒介炎症疾病 (IMIDs) 涉及复杂的治疗决策和不断发展的治疗目标.
- 患者需要确保及时和一致地获得既成熟的,又创新的IMID疗法.
研究的目的:
- 为美国IMID药物的配方决策提出一个以访问为中心的以患者为中心的 (APAC) 价值评估框架.
- 为决策者提供一个务实的工具,以确保公平有效地获得临床指示疗法.
- 在复杂的美国医疗保健环境中,优先考虑患者需求和护理连续性.
主要方法:
- 开发了一个以患者获得IMID药物为中心的价值评估框架.
- 定义了三个核心价值组件:更高的治疗目标,改善与健康有关的生活质量和提高工作生产力.
- 概述了利用临床试验数据和现实世界数据的货币化策略.
主要成果:
- 亚太地区框架为IMID药物的价值评估提供了一个结构化的方法.
- 价值组件的货币化可以从现有和新兴的数据源中获得.
- 该框架旨在促进快速,可预测和持续的治疗方法.
结论:
- 亚太地区框架为美国决策者提供了一个实用的工具.
- 优先考虑患者获取是改善IMID治疗结果,公平性和效率的关键.
- 这种以患者为中心的方法解决了美国医疗保健系统中药物获取的复杂性.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:15Drug Dosage Regimen: Overview
3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119